WO2008105260A1 - Therapeutic agent for ameliorating prognosis after lower limb amputation surgery - Google Patents
Therapeutic agent for ameliorating prognosis after lower limb amputation surgery Download PDFInfo
- Publication number
- WO2008105260A1 WO2008105260A1 PCT/JP2008/052694 JP2008052694W WO2008105260A1 WO 2008105260 A1 WO2008105260 A1 WO 2008105260A1 JP 2008052694 W JP2008052694 W JP 2008052694W WO 2008105260 A1 WO2008105260 A1 WO 2008105260A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- ameliorating
- prognosis
- lower limb
- limb amputation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 238000011542 limb amputation Methods 0.000 title abstract 2
- 210000003141 lower extremity Anatomy 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 238000001356 surgical procedure Methods 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract 1
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed is a therapeutic agent for ameliorating the prognosis after lower limb amputation surgery which is induced by severe peripheral arterial disease. The therapeutic agent comprises a prostaglandin E1 (PGE1) derivative shown by the formula (I) (AS-013) as an active ingredient. Preferably, the therapeutic agent takes a dosage form of a preparation for intravenous or local administration. More preferably, the preparation for injection takes a dosage form of a liposome preparation having the active ingredient AS-013 embedded in a lipid particle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008800063978A CN101622003B (en) | 2007-02-28 | 2008-02-19 | Therapeutic agent for ameliorating prognosis after lower limb amputation surgery |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-049363 | 2007-02-28 | ||
| JP2007049363 | 2007-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008105260A1 true WO2008105260A1 (en) | 2008-09-04 |
Family
ID=39721096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/052694 WO2008105260A1 (en) | 2007-02-28 | 2008-02-19 | Therapeutic agent for ameliorating prognosis after lower limb amputation surgery |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101622003B (en) |
| WO (1) | WO2008105260A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0710833A (en) * | 1991-04-16 | 1995-01-13 | Yutaka Mizushima | Prostaglandin analog, its fat emulsion and its use |
| WO1999009992A1 (en) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Neovascularization promoters |
| WO1999011268A1 (en) * | 1997-08-28 | 1999-03-11 | Yoshitomi Pharmaceutical Industries, Ltd. | Neovascularization promoters and neovascularization potentiators |
-
2008
- 2008-02-19 WO PCT/JP2008/052694 patent/WO2008105260A1/en active Application Filing
- 2008-02-19 CN CN2008800063978A patent/CN101622003B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0710833A (en) * | 1991-04-16 | 1995-01-13 | Yutaka Mizushima | Prostaglandin analog, its fat emulsion and its use |
| WO1999009992A1 (en) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Neovascularization promoters |
| WO1999011268A1 (en) * | 1997-08-28 | 1999-03-11 | Yoshitomi Pharmaceutical Industries, Ltd. | Neovascularization promoters and neovascularization potentiators |
Non-Patent Citations (1)
| Title |
|---|
| ITO M.: "Heisokusei Domyaku Kokasho -Gainen.Bunrui.Shindan.Chiryo-", SHINJIDAI NO TONYOBYOGAKU (4) - BYOIN.SHINDAN.CHIRYO KENKYU NO SHINPO-, KABUSHIKI KASIHA NIPPON RINSHOSHA, 28 October 2002 (2002-10-28), pages 334 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101622003A (en) | 2010-01-06 |
| CN101622003B (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| BRPI0509863A (en) | drug release to the eye fundus | |
| WO2007017135A3 (en) | Process for the preparation of olmesartan medoxomil | |
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| EP1834637A4 (en) | Preventive/therapeutic composition for free radical disease | |
| WO2008069941A3 (en) | Modified release ibuprofen solid oral dosage form | |
| WO2010088000A3 (en) | Antifibrotic compounds and uses thereof | |
| AR047993A1 (en) | PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES | |
| WO2012021107A3 (en) | A liposomal formulation for ocular drug delivery | |
| UA96575C2 (en) | Process for the preparation of olmesartan medoxomil | |
| BR112012016783A2 (en) | "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy" | |
| WO2009028605A1 (en) | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent | |
| BR0210293A (en) | An aqueous pharmaceutical preparation of cilostazol for parenteral use | |
| WO2012012305A3 (en) | Combination therapy using a ruthenium complex | |
| WO2008008701A3 (en) | Substituted cyclopentane derivatives as therapeutic agents | |
| WO2010075315A3 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| EA201171087A1 (en) | METHODS OF ADMINISTRATION (4aR, 10aR) -1-n-PROPIL-1,2,3,4,4a, 5,10,10a-OCTAGHYDROBENZO [g] KHINOLIN-6,7-DIOLA AND RELATED COMPOUNDS THROUGH THE IMMABLE SHELL OF THE CAVITY SLIM OF THE NOSE OR SKIN AND PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| WO2008133297A1 (en) | Therapeutic or prophylactic agent for dyskinesia | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| EA022988B9 (en) | Phenylketone carboxylate compounds and pharmaceutical uses thereof | |
| WO2011049979A3 (en) | Injectable formulations for intra- articular or peri-articular administration | |
| PH12013500711A1 (en) | Acylbenzene derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200880006397.8 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08711518 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08711518 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |